Neoadjuvant Immunotherapy Grows Up
For patients with resectable stage IIIB–D melanoma, giving immune checkpoint inhibitors before surgery is no longer an experimental gambit. It has become standard of care. What has lagged behind that clinical shift is long-term evidence — the kind that tells oncologists whether an early response translates into durable survival years down the road, and whether one treatment strategy outperforms another.
An updated pooled analysis published in Nature Medicine by the International Neoadjuvant Melanoma Consortium (INMC) takes aim at exactly that gap. The open-access paper, posted online on 1 October 2026, revisits three-year and five-year survival figures alongside other outcome data for 1,038 melanoma patients who received neoadjuvant therapy. The work is led by Georgina V. Long and Inês Pires da Silva with Kristen A. Perry, and draws on a long list of co-authors spanning melanoma centres across multiple countries, with Alexander M. Menzies among the senior contributors.
The headline point is structural rather than incidental: the field now has enough mature follow-up, aggregated across institutions, to speak about half-decade outcomes rather than early surrogate endpoints alone.
What the Updated Analysis Covers
The INMC was built precisely for this purpose. Individual trials of neoadjuvant checkpoint inhibition in melanoma are typically modest in size, and their follow-up windows vary. Pooling patient-level data across studies creates a larger denominator — here, 1,038 individuals — and a longer observational horizon than any single trial can offer on its own.
Three years, then five
The paper updates previously reported three-year survival outcomes and extends them to the five-year mark, while also reporting other outcome measures collected by the consortium. That progression matters clinically. In melanoma, recurrences can surface well beyond the first couple of years after surgery, so a three-year snapshot can flatter a treatment that later loses its edge. A five-year readout gives a firmer sense of how durable the benefit of preoperative immunotherapy really is.
A multi-country patient pool
Because the dataset is assembled from numerous participating centres rather than a single protocol, it reflects a broader range of real-world practice patterns — different regimens, differing schedules, and varied patient characteristics within the resectable stage IIIB–D population. That heterogeneity is both the strength and the interpretive challenge of pooled analyses, and the consortium frames its findings accordingly.
The Questions Still Open
The authors are explicit that important knowledge gaps persist despite the maturity of the data. Two stand out.
- Optimal treatment type. Several immune checkpoint inhibitor approaches are used in the neoadjuvant setting, and the analysis does not resolve which regimen should be preferred for a given patient.
- Long-term survival determinants. Understanding which baseline and on-treatment factors predict five-year outcomes remains an active area of investigation.
- Pathologic response as a guide. How the degree of response observed in the surgical specimen should shape what happens after surgery continues to be debated.
These are not peripheral details. They determine whether a patient receives one drug or a combination, how long treatment continues, and whether adjuvant therapy is layered on afterward. A pooled dataset of this size can sharpen those decisions, but it cannot settle every one of them.
Why This Matters Beyond Melanoma
Melanoma has repeatedly served as the proving ground for cancer immunotherapy. Checkpoint inhibitors first demonstrated their capacity to produce durable responses in advanced melanoma, and the neoadjuvant setting has become the next frontier — a place where the immune system is engaged while the tumour burden is still surgically removable.
That logic is now being tested across other tumour types, from lung to bladder cancer. Evidence that preoperative immunotherapy produces survival gains measurable five years out in melanoma strengthens the rationale for those parallel efforts. Conversely, if certain subgroups fail to benefit durably, that signal is equally informative for how trials elsewhere should be designed.
What Clinicians Should Take Away
For practising oncologists, the practical message is one of reinforcement rather than upheaval. Neoadjuvant immune checkpoint inhibition for resectable stage IIIB–D melanoma rests on a foundation that has now been examined over roughly five years in a pooled population exceeding a thousand patients. That is a meaningfully stronger evidentiary base than the field had when the approach was first adopted into routine care.
At the same time, the analysis does not hand clinicians a single formula. Treatment selection remains a matter of weighing regimen-specific evidence, patient factors, and institutional experience, and the consortium's framing acknowledges as much.
The Road Ahead
Pooled consortium data age quickly in a field moving as fast as melanoma immunotherapy. New agents, new combinations, and biomarker-driven strategies will generate fresh questions before the current ones are fully answered. What the INMC has accomplished here is to establish a durable benchmark: a five-year reference point against which the next generation of neoadjuvant approaches will be measured. For patients facing surgery for high-risk melanoma, that benchmark is the clearest sign yet that treating before the operating room is a strategy built to last.
This article is based on reporting by Nature Medicine. Read the original article.
Originally published on nature.com
